✦ LIBER ✦

Is paclitaxel a more cost-effective choice for maintenance therapy than bevacizumab in the primary treatment of advanced ovarian cancer?

✍ Scribed by Kushnir, C.L.; Frick, K.; Zhao, Z.; Giuntoli, R.L.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Is maintenance paclitaxel a more cost-ef

✍ Kushnir, C.; Zhao, N.; Frick, K.; Giuntoli, R. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 46 KB

Consolidation paclitaxel is more cost-ef

✍ J. Lesnock; C. Farris; T. Krivak; K. Smith; M. Markman 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 303 KB

Consolidation paclitaxel is more cost-ef

✍ Jamie L. Lesnock; Coreen Farris; Thomas C. Krivak; Kenneth J. Smith; Maurie Mark 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 344 KB

Is There a Role for Bevacizumab in the P

✍ Meisel, Jane L.; Sabbatini, Paul 📂 Article 📅 2012 🏛 Elsevier 🌐 English ⚖ 87 KB

Cost-effectiveness of a predictive bioma

✍ J. Barnett; A. Alvarez-Secord; D. Cohn; C. Leath; B. Peterson; E. Myers; L. Havr 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 133 KB